Future growth expectations in sales/revenue/volumes?

Expect around 25% growth in sales/revenue in the next quarters or nine-month period (Kamal Aggarwal). Bromide business projected to generate around Rs.70 Crores revenue in 2023 with good margins due to rising crude prices and raw material contracts. New products like Guanine (plant 9) and others in plant 10 expected to contribute significantly to revenue. CMIC capacity expansion to 3000 metric tonnes p.a., making Chemcon the largest domestic producer; import substitution opportunity indicates bright future. TMCS captive production to support expanded HMDS volumes, improving margins but not top

Future growth expectations in earnings/operating earnings/profits/EPS?

Chemcon expects about 25% growth (Kamal Aggarwal, Page 17). The company has maintained strong PAT growth despite production shutdowns; nine months PAT grew from Rs. 40.9 Cr to Rs. 41.5 Cr even with 45 days production loss (Page 16). New product launches like Guanine and expansion of plants 9 and 10 are expected to enhance revenue streams (Page 18). Bromide business is projected to contribute around Rs. 70 Cr in FY 2023 with improving capacity utilization and margins (Page 13). The TMCS facility's contribution is expected to improve bottom lines by reducing raw material import costs (Page 12).

Current/ Expected Orderbook/ Pending Orders?

For CMIC, the company has an order book and dispatch schedules for the current quarter sufficient to run full production capacity. TMCS production at Plant 8 has started and CMIC production is expected by the end of the current month. High purity HMDS has started commercial supply mainly in the rubber industry; semiconductor approval is still pending. 2,5 DHT and 4 CBC products are still in preliminary stages, with efforts to approach new clients and explore international markets ongoing. There are very good inquiries available for the bromide business for supplies in 2023. The bromide segment

Any current/future capex/capital investment/strategic investment?

Completed capex of about Rs.41 Crores on plant number eight and nine as part of IPO proceeds. Plant number eight has started production; expansion of plant nine is in progress and expected to commercialize by Q1 FY2023. Plant number ten mechanical work has started for pharma intermediate products; capital expenditure for P10 estimated at Rs.15 Crores, to be funded from internal accruals. No additional debt planned for completing P9 and P10; available IPO funds (~Rs.55 Crores) and internal accruals suffice. Added capacity of 1200 MTPA at P8 for CMIC to become the world’s largest producer at 300

Any current/future new fundraising through debt or equity?

As per the transcript from February 9, 2022, Chemcon Speciality Chemicals Limited indicated that the capital expenditure (Capex) for Plant 10 will be about Rs. 15 Crores and will be funded from internal accruals. Regarding IPO proceeds, they have about Rs. 55 Crores still unutilized, which will cover working capital needs for plants 8 and 9. The company stated they do not foresee taking up any additional debt for the completion of Plants 9 and 10. There was no mention of any new equity fundraising plans in the discussion. Overall, the company appears focused on using internal funds and

Chemcon Speciality Chemicals LtdQ3 FY22Chemicals & Petrochemicals

Chemcon Speciality Chemicals Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹216P/E: 29.6Market Cap: ₹835 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Expect around 25% growth in sales/revenue in the next quarters or nine-month period (Kamal Aggarwal).
Bromide business projected to generate around Rs.70 Crores revenue in 2023 with good margins due to rising crude prices and raw material contracts.
New products like Guanine (plant 9) and others in plant 10 expected to contribute significantly to revenue.
CMIC capacity expansion to 3000 metric tonnes p.a., making Chemcon the largest domestic producer; import substitution opportunity indicates bright future.
TMCS captive production to support expanded HMDS volumes, improving margins but not topline.
High purity HMDS commercial supply started primarily for rubber and pharmaceutical markets; semiconductor segment yet to pick up.
4 CBC and 2,5 DHT products still in preliminary stages but expected to perform well soon.
Plant 8 and Plant 9 expansions slated for Q1 FY2023, enabling increased production volumes.

Margin guidance

Category 1

Chemcon expects about 25% growth (Kamal Aggarwal, Page 17).
The company has maintained strong PAT growth despite production shutdowns; nine months PAT grew from Rs. 40.9 Cr to Rs. 41.5 Cr even with 45 days production loss (Page 16).
New product launches like Guanine and expansion of plants 9 and 10 are expected to enhance revenue streams (Page 18).
Bromide business is projected to contribute around Rs. 70 Cr in FY 2023 with improving capacity utilization and margins (Page 13).
The TMCS facility's contribution is expected to improve bottom lines by reducing raw material import costs (Page 12).
High purity HMDS supply to rubber industry ongoing; semiconductor applications expected to scale, contributing to higher margins (Pages 8 and 11).
Payback period for recent capex is less than 1.5 years, indicating strong profitability (Page 13).
Overall focus remains on bottomline growth and shareholder value creation (Page 16).

See what Chemcon Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

As per the transcript from February 9, 2022, Chemcon Speciality Chemicals Limited indicated that the capital expenditure (Capex) for Plant 10 will be about Rs. 15 Crores and will be funded from internal accruals.
Regarding IPO proceeds, they have about Rs. 55 Crores still unutilized, which will cover working capital needs for plants 8 and 9.
The company stated they do not foresee taking up any additional debt for the completion of Plants 9 and 10.
There was no mention of any new equity fundraising plans in the discussion.
Overall, the company appears focused on using internal funds and existing IPO proceeds for upcoming expansions without current plans for fresh debt or equity raising.

Order book

Yes

For CMIC, the company has an order book and dispatch schedules for the current quarter sufficient to run full production capacity.
TMCS production at Plant 8 has started and CMIC production is expected by the end of the current month.
High purity HMDS has started commercial supply mainly in the rubber industry; semiconductor approval is still pending.
2,5 DHT and 4 CBC products are still in preliminary stages, with efforts to approach new clients and explore international markets ongoing.
There are very good inquiries available for the bromide business for supplies in 2023.
The bromide segment expects a business turnover of around Rs.70 crore to Rs.80 crore in 2023, with expectations of increased demand due to crude price trends.
Overall, the company is working on incremental products and expanding global footprint with several products in the pipeline for commercialization by Q1 2023 and onwards.

See what Chemcon Speciality Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Completed capex of about Rs.41 Crores on plant number eight and nine as part of IPO proceeds.
Plant number eight has started production; expansion of plant nine is in progress and expected to commercialize by Q1 FY2023.
Plant number ten mechanical work has started for pharma intermediate products; capital expenditure for P10 estimated at Rs.15 Crores, to be funded from internal accruals.
No additional debt planned for completing P9 and P10; available IPO funds (~Rs.55 Crores) and internal accruals suffice.
Added capacity of 1200 MTPA at P8 for CMIC to become the world’s largest producer at 3000 MTPA.
Bromine plant awaiting pollution control permissions to start manufacturing bromine-based products in P8; new product launch expected from Q1 FY2023 after clearance.
Investment aimed at import substitution and expanding domestic/domestic export product portfolio.

Track Chemcon Speciality Chemicals Ltd — get its next earnings analysis in your feed

How does Chemcon Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisChemcon Speciality Chemicals Ltd

Rev 2Mar 1

See where Chemcon Speciality Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Chemcon Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Chemcon Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q3 FY22) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Chemcon Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →